{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T14:45:16Z","timestamp":1760453116662,"version":"3.37.3"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2021,7,2]],"date-time":"2021-07-02T00:00:00Z","timestamp":1625184000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,2]],"date-time":"2021-07-02T00:00:00Z","timestamp":1625184000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"MEXT | Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["16K21639, 16K09598, 17K10617"],"award-info":[{"award-number":["16K21639, 16K09598, 17K10617"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>A majority of mesothelioma specimens were defective of p14 and p16 expression due to deletion of the INK4A\/ARF region, and the p53 pathway was consequently inactivated by elevated MDM2 functions which facilitated p53 degradaton. We investigated a role of p53 elevation by MDM2 inhibitors, nutlin-3a and RG7112, in cytotoxicity of replication-competent adenoviruses (Ad) lacking the p53-binding <jats:italic>E1B55kDa<\/jats:italic> gene (Ad-delE1B). We found that a growth inhibition by p53-activating Ad-delE1B was irrelevant to p53 expression in the infected cells, but combination of Ad-delE1B and the MDM2 inhibitor produced synergistic inhibitory effects on mesothelioma with the wild-type but not mutated <jats:italic>p53<\/jats:italic> genotype. The combination augmented p53 phosphorylation, activated apoptotic but not autophagic pathway, and enhanced DNA damage signals through ATM-Chk2 phosphorylation. The MDM2 inhibitors facilitated production of the Ad progenies through augmented expression of nuclear factor I (NFI), one of the transcriptional factors involved in Ad replications. Knocking down of p53 with siRNA did not increase the progeny production or the NFI expression. We also demonstrated anti-tumor effects by the combination of Ad-delE1B and the MDM2 inhibitors in an orthotopic animal model. These data collectively indicated that upregulation of wild-type p53 expression contributed to cytotoxicity by E1B55kDa-defective replicative Ad through NFI induction and suggested that replication-competent Ad together with augmented p53 levels was a therapeutic strategy for <jats:italic>p53<\/jats:italic> wild-type mesothelioma.<\/jats:p>","DOI":"10.1038\/s41419-021-03934-y","type":"journal-article","created":{"date-parts":[[2021,7,6]],"date-time":"2021-07-06T09:04:07Z","timestamp":1625562247000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["An MDM2 inhibitor achieves synergistic cytotoxic effects with adenoviruses lacking E1B55kDa gene on mesothelioma with the wild-type p53 through augmenting NFI expression"],"prefix":"10.1038","volume":"12","author":[{"given":"Thao Thi Thanh","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masato","family":"Shingyoji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michiko","family":"Hanazono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boya","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takao","family":"Morinaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuji","family":"Tada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideaki","family":"Shimada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenzo","family":"Hiroshima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2906-1555","authenticated-orcid":false,"given":"Masatoshi","family":"Tagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,7,2]]},"reference":[{"key":"3934_CR1","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1002\/cncr.22552","volume":"109","author":"AY Lee","year":"2007","unstructured":"Lee AY, Raz DJ, He B, Jablons DM. Update on the molecular biology of malignant mesothelioma. Cancer. 2007;109:1454\u201361.","journal-title":"Cancer"},{"key":"3934_CR2","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1158\/0008-5472.CAN-14-1008","volume":"76","author":"G Guo","year":"2015","unstructured":"Guo G, Chmielecki J, Goparaju C, Heguy A, Dolgalev I, Carbone M, et al. Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma. Cancer Res. 2015;76:264\u20139.","journal-title":"Cancer Res"},{"key":"3934_CR3","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/ng.3520","volume":"48","author":"R Bueno","year":"2016","unstructured":"Bueno R, Stawiski EW, Goldstein LD, Durinck S, de Rienzo A, Modrusan Z, et al. Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. Nat. Genet. 2016;48:407\u201316.","journal-title":"Nat. Genet"},{"key":"3934_CR4","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1038\/cgt.2013.1","volume":"20","author":"M Tagawa","year":"2013","unstructured":"Tagawa M, Tada Y, Shimada H, Hiroshima K. Gene therapy for malignant mesothelioma: current prospects and challenges. Cancer Gene Ther. 2013;20:150\u20136.","journal-title":"Cancer Gene Ther"},{"key":"3934_CR5","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/cgt.2011.86","volume":"19","author":"Q Li","year":"2012","unstructured":"Li Q, Kawamura K, Yamanaka M, Okamoto S, Yang S, Yamauchi S, et al. Upregulated p53 expression activates apoptotic pathways in wild-type p53-bearing mesothelioma and enhances cytotoxicity of cisplatin and pemetrexed. Cancer Gene Ther. 2012;19:218\u201328.","journal-title":"Cancer Gene Ther"},{"key":"3934_CR6","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1186\/s12885-015-1482-8","volume":"15","author":"S Yang","year":"2015","unstructured":"Yang S, Kawamura K, Okamoto S, Yamauchi S, Shingyoji M, Senike I, et al. Cytotoxic effects of replication-competent adenoviruses on human esophageal carcinoma are enhanced by forced p53 expression. BMC Cancer. 2015;15:464.","journal-title":"BMC Cancer"},{"key":"3934_CR7","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1089\/104303401750270995","volume":"12","author":"J Mi","year":"2001","unstructured":"Mi J, Li ZY, Ni S, Steinwaerder D, Lieber A. Induced apoptosis supports spread of adenovirus vectors in tumors. Hum. Gene Ther. 2001;12:1343\u201352.","journal-title":"Hum. Gene Ther."},{"key":"3934_CR8","first-page":"6165","volume":"62","author":"VW van Beusechem","year":"2002","unstructured":"van Beusechem VW, van den Doel PB, Grill J, Pinedo HM, Gerritsen WR. Conditionally replicative adenovirus expressing p53 exhibits enhanced oncolytic potency. Cancer Res. 2002;62:6165\u201371.","journal-title":"Cancer Res"},{"key":"3934_CR9","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1158\/1535-7163.MCT-10-0205","volume":"9","author":"R Sakai","year":"2010","unstructured":"Sakai R, Kagawa S, Yamasaki Y, Kojima T, Uno F, Hashimoto Y, et al. Preclinical evaluation of differentially targeting dual virotherapy for human solid cancer. Mol. Canc Ther. 2010;9:1884\u201393.","journal-title":"Mol. Canc Ther"},{"key":"3934_CR10","doi-asserted-by":"publisher","first-page":"19976","DOI":"10.18632\/oncotarget.5116","volume":"6","author":"C Larson","year":"2015","unstructured":"Larson C, Oronsky B, Scicinski J, Fanger GR, Stirn M, Oronsky A, et al. Going viral: a review of replication-selective oncolytic adenoviruses. Oncotarget. 2015;6:19976\u201389.","journal-title":"Oncotarget."},{"key":"3934_CR11","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1097\/JTO.0b013e3182725fa4","volume":"7","author":"M Yamanaka","year":"2012","unstructured":"Yamanaka M, Tada Y, Kawamura K, Li Q, Okamoto S, Chai K, et al. E1B-55 kDa-defective adenoviruses activate p53 in mesothelioma and enhance cytotoxicity of anticancer agents. J Thorac Oncol. 2012;7:1850\u20137.","journal-title":"J Thorac Oncol"},{"key":"3934_CR12","doi-asserted-by":"publisher","first-page":"8810","DOI":"10.1158\/0008-5472.CAN-07-1140","volume":"67","author":"B Hu","year":"2007","unstructured":"Hu B, Gilkes DM, Chen J. Efficient p53 activation and apoptosis by simultaneous disruption of binding to MDM2 and MDMX. Cancer Res. 2007;67:8810\u20137.","journal-title":"Cancer Res"},{"key":"3934_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2174\/157489210789702172","volume":"5","author":"A di Cintio","year":"2010","unstructured":"di Cintio A, di Gennaro E, Budillon A. Restoring p53 function in cancer: novel therapeutic approaches for applying the brakes to tumorigenesis. Recent Pat Anticancer Drug Discov. 2010;5:1\u201313.","journal-title":"Recent Pat Anticancer Drug Discov"},{"key":"3934_CR14","doi-asserted-by":"publisher","first-page":"9470","DOI":"10.1128\/JVI.72.12.9470-9478.1998","volume":"72","author":"T Rothmann","year":"1998","unstructured":"Rothmann T, Hengstermann A, Whitaker NJ, Scheffner A, Hausen H. Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells. J Virol. 1998;72:9470\u20138.","journal-title":"J Virol"},{"key":"3934_CR15","first-page":"5959","volume":"61","author":"C-Ta Yang","year":"2001","unstructured":"Yang C-Ta, You L, Uematsu K, Yeh C-C, McCormick F, Jablons DM. p14ARF modulates the cytolytic effect of ONYX-015 in mesothelioma cells with wild-type p53. Cancer Res. 2001;61:5959\u201363.","journal-title":"Cancer Res."},{"key":"3934_CR16","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.omto.2017.03.002","volume":"5","author":"C Bressy","year":"2017","unstructured":"Bressy C, Hastie E, Grdzelishvili VZ. Combining oncolytic virotherapy with p53 tumor suppressor gene therapy. Mol Ther Oncolytics. 2017;5:20\u201340.","journal-title":"Mol Ther Oncolytics"},{"key":"3934_CR17","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1158\/1535-7163.MCT-05-0010","volume":"4","author":"VW van Beusechem","year":"2005","unstructured":"van Beusechem VW, van den Doel PB, Gerritsen WR. Conditionally replicative adenovirus expressing degradation-resistant p53 for enhanced oncolysis of human cancer cells overexpressing murine double minute 2. Mol Cancer Ther. 2005;4:1013\u20138.","journal-title":"Mol Cancer Ther"},{"key":"3934_CR18","doi-asserted-by":"publisher","first-page":"2282","DOI":"10.1016\/j.ejca.2011.12.020","volume":"48","author":"Y Yamasaki","year":"2012","unstructured":"Yamasaki Y, Tazawa H, Hashimoto Y, Kojima T, Kuroda S, Yano S, et al. A novel apoptotic mechanism of genetically engineered adenovirus-mediated tumour-specific p53 overexpression through E1A-dependent p21 and MDM2 suppression. Eur J Cancer. 2012;48:2282\u201391.","journal-title":"Eur J Cancer"},{"key":"3934_CR19","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1158\/1535-7163.MCT-12-0869","volume":"12","author":"J Hasei","year":"2013","unstructured":"Hasei J, Sasaki T, Tazawa H, Osaki S, Yamakawa Y, Kunisada T, et al. Dual programmed cell death pathways induced by p53 transactivation overcome resistance to oncolytic adenovirus in human osteosarcoma cells. Mol Cancer Ther. 2013;12:314\u201325.","journal-title":"Mol Cancer Ther"},{"key":"3934_CR20","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1128\/JVI.01836-15","volume":"90","author":"C B\u00fcrck","year":"2015","unstructured":"B\u00fcrck C, Mund A, Berscheminski J, Kieweg L, M\u00fcncheberg S, Dobner T, et al. KAP1 is a host restriction factor that promotes human adenovirus E1B-55K SUMO modification. J Virol. 2015;90:930\u201346.","journal-title":"J Virol"},{"key":"3934_CR21","doi-asserted-by":"publisher","first-page":"26267","DOI":"10.1074\/jbc.R111.252569","volume":"28","author":"S Iyengar","year":"2011","unstructured":"Iyengar S, Farnham PJ. KAP1 protein: an enigmatic master regulator of the genome. J Biol Chem. 2011;28:26267\u201376.","journal-title":"J Biol Chem"},{"key":"3934_CR22","first-page":"131","volume":"272","author":"H Liu","year":"2003","unstructured":"Liu H, Naismith JH, Hay RT. Adenovirus DNA replication. Curr Top Microbiol Immunol. 2003;272:131\u201364.","journal-title":"Curr Top Microbiol Immunol"},{"key":"3934_CR23","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.3892\/or.2015.3715","volume":"33","author":"Q Zhang","year":"2015","unstructured":"Zhang Q, Cao LY, Cheng SJ, Zhang AM, Jin XS, Li Y. p53-induced microRNA-1246 inhibits the cell growth of human hepatocellular carcinoma cells by targeting NFIB. Oncol Rep. 2015;33:1335\u201341.","journal-title":"Oncol Rep"},{"key":"3934_CR24","doi-asserted-by":"publisher","first-page":"5663","DOI":"10.1128\/MCB.02095-05","volume":"26","author":"J Nilsson","year":"2006","unstructured":"Nilsson J, Bjursell G, Kannius-Janson M. Nuclear Jak2 and transcription factor NFI-C2: a novel mechanism of prolactin signaling in mammary epithelial cells. Mol Cell Biol. 2006;26:5663\u201374.","journal-title":"Mol Cell Biol"},{"key":"3934_CR25","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1093\/neuonc\/not167","volume":"16","author":"JS Lee","year":"2014","unstructured":"Lee JS, Xiao J, Patel P, Schade J, Wang J, Deneen B, et al. A novel tumor-promoting role for nuclear factor IA in glioblastomas is mediated through negative regulation of p53, p21, and PAI1. Neuro-Oncol. 2014;16:191\u2013203.","journal-title":"Neuro-Oncol"},{"key":"3934_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2164-12-181","volume":"12","author":"M Pjanic","year":"2011","unstructured":"Pjanic M, Pjanic P, Schmid C, Ambrosini G, Gaussin A, Plasari G, et al. Nuclear factor I revealed as family of promoter binding transcription activators. BMC Genomics. 2011;12:181.","journal-title":"BMC Genomics"},{"key":"3934_CR27","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1038\/sj.emboj.7600791","volume":"24","author":"C Wang","year":"2005","unstructured":"Wang C, Ivanov A, Chen L, Fredericks WJ, Seto E, Rauscher FJ, et al. MDM2 interaction with nuclear corepressor KAP1 contributes to p53 inactivation. EMBO J. 2005;24:3279\u201390.","journal-title":"EMBO J"},{"key":"3934_CR28","first-page":"115","volume":"2","author":"G Ma","year":"2008","unstructured":"Ma G, Shimada H, Hiroshima K, Tada Y, Suzuki N, Tagawa M. Gene medicine for cancer treatment: Commercially available medicine and accumulated clinical data in China. Drug Des Dev Ther. 2008;2:115\u201322.","journal-title":"Drug Des Dev Ther"},{"key":"3934_CR29","doi-asserted-by":"publisher","first-page":"80","DOI":"10.2174\/1389450114666140106101412","volume":"15","author":"B Hong","year":"2014","unstructured":"Hong B, van den Heuvel AP, Prabhu VV, Zhang S, El-Deiry WS. Targeting tumor suppressor p53 for cancer therapy: strategies, challenges and opportunities. Curr Drug Targets. 2014;15:80\u201389.","journal-title":"Curr Drug Targets"},{"key":"3934_CR30","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s13045-017-0500-5","volume":"10","author":"V Tisato","year":"2017","unstructured":"Tisato V, Voltan R, Gonelli A, Secchiero P, Giorgio ZG. MDM2\/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer. J Hematol Oncol. 2017;10:133.","journal-title":"J Hematol Oncol"},{"key":"3934_CR31","doi-asserted-by":"publisher","first-page":"3791","DOI":"10.1158\/1078-0432.CCR-15-2133","volume":"2","author":"DH Sterman","year":"2016","unstructured":"Sterman DH, Alley E, Stevenson JP, Friedberg J, Metzger S, Recio A, et al. Pilot and feasibility trial evaluating immuno-gene therapy of malignant mesothelioma using intrapleural delivery of adenovirus-IFN\u03b1 combined with chemotherapy. Clin Cancer Res. 2016;2:3791\u20133800.","journal-title":"Clin Cancer Res"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-021-03934-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-021-03934-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-021-03934-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T09:03:32Z","timestamp":1669971812000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-021-03934-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,2]]},"references-count":31,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2021,7]]}},"alternative-id":["3934"],"URL":"https:\/\/doi.org\/10.1038\/s41419-021-03934-y","relation":{},"ISSN":["2041-4889"],"issn-type":[{"type":"electronic","value":"2041-4889"}],"subject":[],"published":{"date-parts":[[2021,7,2]]},"assertion":[{"value":"24 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that there is no conflict of interests in this research. We obtained a grant from Nichias Corporation. It is not a pharmaceutical company but a company making industrial products for building, automobiles and pipes (see ). The grant is as a kind of their m\u00e9c\u00e9nat activities, corporate social contributions, which is aimed to assist for medical research for intractable cancer treatments. We are thereby irrelevant to any employment, consultancy, patents or products in development or marketed products to the company.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the Institutional Ethical Committee and Recombinant DNA committee of Chiba Cancer Center Research Institute and Chiba University (Gene 1\u20132 and 1\u20133), and was conducted according to conditions for the use of living modified organisms by Biosafety Regulations in Japan. The animal experiments were approved by the animal experiment and welfare committee of Chiba Cancer Center Research Institute (16-1) and Chiba University (2-302), and were performed according to the guideline on the animal experiments.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}}],"article-number":"663"}}